Copyright
©The Author(s) 2016.
World J Gastroenterol. May 28, 2016; 22(20): 4794-4801
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4794
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4794
Table 2 Cancer secondary to immunosuppression
| Increased risk under anti-metabolites | Increased risk under anti-TNFα | Increased risk under anti-metabolite with anti-TNFα |
| Non-Hodgkin lymphoma[33-35] | Melanoma[42] | Hepatosplenic T-cell lymphoma[38] |
| Acute myeloid leukemia and Myelodysplastic syndromes[61] | ||
| Non-melanoma skin cancers (basal and squamous cell carcinomas)[39-41] | ||
| Urinary tract cancers[62] |
- Citation: Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016; 22(20): 4794-4801
- URL: https://www.wjgnet.com/1007-9327/full/v22/i20/4794.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i20.4794